Bayer targets COPD in a new discovery alliance with Haplogen, Evotec

Bayer is adding COPD to its list of discovery targets. 

Georg Casari

The German pharma company has tied the knot with a collaborative effort that’s been underway between Vienna-based Haplogen and Evotec — a high profile discovery shop in Europe. They’ll all be working together now on new therapeutics for pulmonary diseases, with a special focus on COPD.

Researchers will be exploring for new antivirals that can prevent the replication of a virus involved in COPD. And Bayer will cover an undisclosed upfront and other terms to push the alliance forward.

Bayer gets worldwide rights to anything they whip up in the alliance.

“This partnership with Bayer will transform our discoveries to therapies with benefit to patients in need,” said Haplogen CEO Georg Casari.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,800+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Director, Program Management
Contrafect Corporation New York, NY
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA

Visit Endpoints Careers ->